What does the $374 offer mean for Penumbra stock holders?

Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, subject to approvals. Until closing, the market price can trade below $374 to reflect timing and risk. On completion, holders should receive consideration equal to the agreed value under final terms.

Why is Boston Scientific buying Penumbra?

The acquisition adds thrombectomy and embolization devices, expanding Boston Scientific’s vascular and neuro portfolios. Management aims to deepen hospital relationships, cross-sell across service lines, and accelerate growth. Investors will watch for integration progress, margin protection, and evidence that combined scale translates into durable revenue and earnings gains.

How might PEN share price trade before the deal closes?

PEN often trades at a discount to the $374 offer. The spread reflects closing probability, expected timing, and the mix of cash and stock. News on regulatory review, earnings, or competing bids could move the PEN share price closer to, or further from, the deal value.

What are the key risks to the Boston Scientific deal?

The main risks are regulatory approval, integration execution, and potential changes to deal terms. Market volatility and funding details can also affect the spread. Any delay, regulatory pushback, or negative earnings update could widen the discount to terms or pressure both stocks.

Global Market Insights

PEN Stock Today: January 16 Boston Scientific’s $14.5B Buyout at $374

ByHuzaifa Zahoor January 16, 2026January 16, 2026

Penumbra stock is in focus after Boston Scientific said it will buy the company for $14.5 billion, or $374 per share, paid in cash and stock. The offer adds thrombectomy and embolization to Boston Scientific’s portfolio and spotlights medtech M&A. At a recent price of $350.89, PEN traded below the offer as investors weigh timing and regulatory risk. We break down the Boston Scientific deal terms, PEN share price dynamics, the impact on BSX, and the next catalysts US investors should watch.